TY - JOUR
T1 - Theory and in vivo application of electroporative gene delivery
AU - Somiari, Stella
AU - Glasspool-Malone, Jill
AU - Drabick, Joseph J.
AU - Gilbert, Richard A.
AU - Heller, Richard
AU - Jaroszeski, Mark J.
AU - Malone, Robert W.
N1 - Funding Information:
CytoPulse and University of Maryland, Baltimore have had a collaboration agreement under which CytoPulse's equipment has been used by Robert Malone, M.D., in scientific research and development, principally in the areas of delivering DNA using pulsed electric fields. This work has been supported by NIHK02AI01370 (R.W.M.), NIH-R01RR12307 (R.W.M.), and developmental funds provided by the University of Maryland Medical System (R.W.M.).
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2000/9
Y1 - 2000/9
N2 - Efficient and safe methods for delivering exogenous genetic material into tissues must be developed before the clinical potential of gene therapy will be realized. Recently, in vivo electroporation has emerged asa leading technology for developing nonviral gene therapies and nucleic acid vaccines (NAV). Electroporation (EP) involves the application of pulsed electric fields to cells to enhance cell permeability, resulting in exogenous polynucleotide transit across the cytoplasmic membrane. Similar pulsed electrical field treatments are employed in a wide range of biotechnological processes including in vitro EP, hybridoma production, development of transgenic animals, and clinical electrochemotherapy. Electroporative gene delivery studies benefit from well-developed literature that may be used to guide experimental design and interpretation. Both theory and experimental analysis predict that the critical parameters governing EP efficacy include cell size and field strength, duration, frequency, and total number of applied pulses. These parameters must be optimized for each tissue in order to maximize gene delivery while minimizing irreversible cell damage. By providing an overview of the theory and practice of electroporative gene transfer, this review intendsto aid researchers that wish to employ the method for preclinical and translational gene therapy, NAV, and functional genomic research.
AB - Efficient and safe methods for delivering exogenous genetic material into tissues must be developed before the clinical potential of gene therapy will be realized. Recently, in vivo electroporation has emerged asa leading technology for developing nonviral gene therapies and nucleic acid vaccines (NAV). Electroporation (EP) involves the application of pulsed electric fields to cells to enhance cell permeability, resulting in exogenous polynucleotide transit across the cytoplasmic membrane. Similar pulsed electrical field treatments are employed in a wide range of biotechnological processes including in vitro EP, hybridoma production, development of transgenic animals, and clinical electrochemotherapy. Electroporative gene delivery studies benefit from well-developed literature that may be used to guide experimental design and interpretation. Both theory and experimental analysis predict that the critical parameters governing EP efficacy include cell size and field strength, duration, frequency, and total number of applied pulses. These parameters must be optimized for each tissue in order to maximize gene delivery while minimizing irreversible cell damage. By providing an overview of the theory and practice of electroporative gene transfer, this review intendsto aid researchers that wish to employ the method for preclinical and translational gene therapy, NAV, and functional genomic research.
UR - http://www.scopus.com/inward/record.url?scp=0034268548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034268548&partnerID=8YFLogxK
U2 - 10.1006/mthe.2000.0124
DO - 10.1006/mthe.2000.0124
M3 - Review article
C2 - 10985947
AN - SCOPUS:0034268548
SN - 1525-0016
VL - 2
SP - 178
EP - 187
JO - Molecular Therapy
JF - Molecular Therapy
IS - 3
ER -